BRE MI01
Alternative Names: BRE-MI01Latest Information Update: 30 Nov 2022
Price :
$50 *
At a glance
- Originator Brexogen
- Class Anti-inflammatories; Anti-ischaemics
- Mechanism of Action Exosome replacements; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Myocardial infarction
Most Recent Events
- 23 Nov 2022 Early research in Myocardial infarction in South Korea, prior to November 2022 (Brexogen pipeline, November 2022)
- 23 Nov 2022 Brexogen plans preclinical trials in Q1 2023 (Brexogen pipeline, November 2022)
- 23 Nov 2022 Brexogen plans to submit IND application in Q1 2024 (Brexogen pipeline, November 2022)